不可靠，不信谣不传谣
CCTV，people's daily,Global Times 都没有报道
不可靠，不信谣不传谣
只看到这个数据 0.011 per cent of about 7.2 million
https://www.straitstimes.com/asia/se-asia/sinovacs-covid-19-shot-highly-effective-against-serious-illness-malaysia-study
PUBLISHEDSEP 24, 2021, 2:49 PM SGT
KUALA LUMPUR (REUTERS) - Sinovac's Covid-19 vaccine is highly effective against serious illness, although rival shots from Pfizer-BioNTech and AstraZeneca showed better protection rates, a large, real-world study from Malaysia showed.
The latest data is a boost to the Chinese firm, whose Covid-19 vaccine has been under growing scrutiny over its effectiveness following reports of infections among healthcare workers fully immunised with the Sinovac shot in Indonesia and Thailand.
The study, conducted by the Malaysian government, found that 0.011 per cent of about 7.2 million recipients of the Sinovac shot required treatment in intensive care units (ICU) for Covid-19 infections, health officials told reporters on Thursday (Sept 23).
y contrast, 0.002 per cent of about 6.5 million recipients of the Pfizer-BioNTech vaccine needed ICU treatment for Covid-19 infections, while 0.001 per cent of 744,958 recipients of the AstraZeneca shot required similar treatment.
Dr Kalaiarasu Peariasamy, a director at the Institute for Clinical Research that conducted the study along with a national Covid-19 task force, said vaccinations - regardless of the brand - have reduced the risk of admission to intensive care by 83 per cent and lowered the risk of death by 88 per cent based on a smaller study involving about 1.26 million people.
"The breakthrough rate for intensive care unit admission is extremely low," he said, adding that overall ICU admissions among fully vaccinated individuals stood at 0.0066 per cent.
PUBLISHEDSEP 24, 2021, 2:49 PM SGT
KUALA LUMPUR (REUTERS) - Sinovac's Covid-19 vaccine is highly effective against serious illness, although rival shots from Pfizer-BioNTech and AstraZeneca showed better protection rates, a large, real-world study from Malaysia showed.
The latest data is a boost to the Chinese firm, whose Covid-19 vaccine has been under growing scrutiny over its effectiveness following reports of infections among healthcare workers fully immunised with the Sinovac shot in Indonesia and Thailand.
The study, conducted by the Malaysian government, found that 0.011 per cent of about 7.2 million recipients of the Sinovac shot required treatment in intensive care units (ICU) for Covid-19 infections, health officials told reporters on Thursday (Sept 23).
y contrast, 0.002 per cent of about 6.5 million recipients of the Pfizer-BioNTech vaccine needed ICU treatment for Covid-19 infections, while 0.001 per cent of 744,958 recipients of the AstraZeneca shot required similar treatment.
Dr Kalaiarasu Peariasamy, a director at the Institute for Clinical Research that conducted the study along with a national Covid-19 task force, said vaccinations - regardless of the brand - have reduced the risk of admission to intensive care by 83 per cent and lowered the risk of death by 88 per cent based on a smaller study involving about 1.26 million people.
"The breakthrough rate for intensive care unit admission is extremely low," he said, adding that overall ICU admissions among fully vaccinated individuals stood at 0.0066 per cent.
只看到这个数据 0.011 per cent of about 7.2 millionhttps://www.straitstimes.com/asia/se-asia/sinovacs-covid-19-shot-highly-effective-against-serious-illness-malaysia-study
PUBLISHEDSEP 24, 2021, 2:49 PM SGT
KUALA LUMPUR (REUTERS) - Sinovac's Covid-19 vaccine is highly effective against serious illness, although rival shots from Pfizer-BioNTech and AstraZeneca showed better protection rates, a large, real-world study from Malaysia showed.
The latest data is a boost to the Chinese firm, whose Covid-19 vaccine has been under growing scrutiny over its effectiveness following reports of infections among healthcare workers fully immunised with the Sinovac shot in Indonesia and Thailand.
The study, conducted by the Malaysian government, found that 0.011 per cent of about 7.2 million recipients of the Sinovac shot required treatment in intensive care units (ICU) for Covid-19 infections, health officials told reporters on Thursday (Sept 23).
y contrast, 0.002 per cent of about 6.5 million recipients of the Pfizer- (more...)
不过从新加坡数据来看
两针mrna打完后去世的现在每天都有了
[本文发送自华新手机Wap版]
我印象中马来西亚开始打的主要是科兴，后来科兴打完了。后期主要是辉瑞。
开始打的人群应该高危的多。新加坡也打了不少科兴，目前还没有看到任何数据。
我印象中马来西亚开始打的主要是科兴，后来科兴打完了。后期主要是辉瑞。开始打的人群应该高危的多。新加坡也打了不少科兴，目前还没有看到任何数据。
新加坡精英圆滑世故，可没有马来西亚直肠子
弹丸小国拿嘴得罪人划不来
所以，类似数据永远不会有
所以，类似数据永远不会有
+1，首先既然ICU主要是60+的，直接拿60+的接种数据不好么不知道这些图要干嘛。。。
宣传吧，本地报纸的角度一直是没有变的
鼓励大家打mRNA疫苗，同时证明精英的选择是正确的。
因为属于高危人群
[本文发送自华新iOS App]
华新中文网致力于为新加坡留学生、工作人士及华人同胞提供交流空间和服务平台
关于我们┊ 广告服务┊ 联系方式┊ 华新博客┊ 经典怀旧┊ 投递作品
Huasing Association 1999 - 2013
